145 related articles for article (PubMed ID: 6582804)
1. [Interferons--its method of administration and adverse effect related to pharmacokinetics ].
Furue H
Gan To Kagaku Ryoho; 1984 Feb; 11(2):186-93. PubMed ID: 6582804
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of human interferons].
Furue H; Kobayashi H; Komuro T; Kako M; Mugitani H; Fuse K; Kaise R; Nagai K; Takahashi T; Hirota F
Gan To Kagaku Ryoho; 1984 Apr; 11(4):935-42. PubMed ID: 6721508
[TBL] [Abstract][Full Text] [Related]
3. [Phase I study of human lymphoblastoid alpha-interferon on malignant tumor].
Furue H
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):977-83. PubMed ID: 3963861
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
5. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon.
Silver HK; Connors JM; Salinas FA
Cancer Treat Rep; 1985; 69(7-8):743-50. PubMed ID: 4016785
[TBL] [Abstract][Full Text] [Related]
6. [Recombinant interferon alpha-2 (Sch 30500) in patients with head and neck cancer].
Miyake H; Horiuchi M; Togawa K; Kawamoto K; Kaneko T; Inuyama Y; Honda Y; Baba S; Matsunaga T; Ishikawa T
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1651-5. PubMed ID: 3896156
[TBL] [Abstract][Full Text] [Related]
7. American cancer society Phase I trial of naturally produced beta-interferon.
Hawkins MJ; Krown SE; Borden EC; Krim M; Real FX; Edwards BS; Anderson SA; Cunningham-Rundles S; Oettgen HF
Cancer Res; 1984 Dec; 44(12 Pt 1):5934-8. PubMed ID: 6498851
[TBL] [Abstract][Full Text] [Related]
8. Interferons in the treatment of genital human papillomavirus infections.
Weck PK; Buddin DA; Whisnant JK
Am J Med; 1988 Aug; 85(2A):159-64. PubMed ID: 3044081
[TBL] [Abstract][Full Text] [Related]
9. [Phase-1 study of the tolerance for increasing doses of recombinant human alpha 2 interferon in patients with advanced cancer].
Bretaudeau B; Palangie T; Giralt E; Jouve M; Pouillart P; Falcoff E; Fridman WH; Magdelenat H; Derstepani L; Laurent T
Bull Cancer; 1984; 71(1):40-9. PubMed ID: 6713113
[TBL] [Abstract][Full Text] [Related]
10. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
12. [Interferon-alpha].
Furue H; Mugitani H; Hirota F; Suminaga M
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):797-803. PubMed ID: 3291773
[TBL] [Abstract][Full Text] [Related]
13. Interferon: mechanisms of action and clinical value.
Houglum JE
Clin Pharm; 1983; 2(1):20-8. PubMed ID: 6192965
[TBL] [Abstract][Full Text] [Related]
14. The lymphatic route. VI. Distribution of recombinant interferon-alpha 2 in rabbit and pig plasma and lymph.
Bocci V; Pessina GP; Paulesu L; Nicoletti C
J Biol Response Mod; 1988 Aug; 7(4):390-400. PubMed ID: 3171601
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics and pharmacological aspects of interferons].
Kiuch Y
Gan To Kagaku Ryoho; 1984 Jan; 11(1):36-43. PubMed ID: 6421242
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
18. Side effects of alpha interferon in chronic hepatitis C.
Dusheiko G
Hepatology; 1997 Sep; 26(3 Suppl 1):112S-121S. PubMed ID: 9305675
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of human recombinant interferon-beta in monkeys and rabbits.
Gomi K; Morimoto M; Inoue A; Kobayashi H; Deguchi T; Hara T; Nakamizo N
Gan; 1984 Mar; 75(3):292-300. PubMed ID: 6724230
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of recombinant interferon alpha-2 (Sch 30500) in advanced gynecological cancers].
Kasamatsu T; Ohmi K; Takeuchi S; Takamizawa H; Matsuzawa M; Kawana T; Ueda K; Kubo H; Tsumuji Y; Kawashima Y
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1656-60. PubMed ID: 3896157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
